A UK health watchdog has recommended the use of AstraZeneca‘s Brilique (ticagrelor) in combination with a low-dose aspirin for the treatment of acute coronary syndromes.

In its final guidance, the National Institute for Health and Clinical Excellence (NICE) approved the drug for use for up to 12 months as a treatment option for patients who have had a hear attack or an episode of unstable angina.

Primary care trusts in the UK will have a three-month period to ensure that Brilique is made available for physicians working for the NHS.

The NHS is legally obliged to reimburse and resource medicines and treatments recommended by NICE’s technology appraisals.

Norfolk and Norwich University Hospitals NHS Foundation Trust consultant cardiologist Professor Marcus Flather commented, "The approval of ticagrelor provides healthcare professionals working in England and Wales with an important tool to enable them to treat people who have had a heart attack and episode of unstable angina.

"Ticagrelor has been shown to be a more effective treatment option than clopidogrel and will help us to reduce the rates of repeat heart attack and cardiovascular death in the thousands of patients we treat each year," he added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.